Back to top

Image: Bigstock


Read MoreHide Full Article

Sanofi’s focus on streamlining its business and pursuing business development deals is encouraging. Sanofi has several new products in its portfolio and candidates in its pipeline that can contribute to long-term growth. New drugs like Aubagio and Lemtrada are likely to continue doing well. We are also optimistic on sales prospects of Dupixent, which could prove to be an important growth driver. The recent FDA and EU approval of Kevzara for rheumatoid arthritis is also encouraging. Sanofi’s shares have outperformed the large-cap pharma industry this year so far. Estimates have remained stable ahead of the company’s Q2 earnings release. The company has a positive record of earnings surprises in the recent quarters. However, headwinds include a bleak outlook for the Diabetes franchise, generic competition for many drugs and slower-than-expected uptake of new products like Praluent.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Sanofi (SNY) - free report >>